Fuji Pharma Co., Ltd. (4554) AI Stock Analysis

• Market Cap: €40.18B
• Dividend Yield: 2.83%
• Average Volume (3M): 73.94K
• Price to Earnings (P/E): 13.1
• Beta (1Y): 0.76
• Revenue Growth: 12.06%
• EPS Growth: -51.89%
• Country: JP
• Employees: 1,658
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 22.24
• Shares Outstanding: 24,891,100
• 10 Day Avg. Volume: 70,650
• 30 Day Avg. Volume: 73,943
• PEG Ratio: 0.06
• Price to Book (P/B): 0.68
• Price to Sales (P/S): 0.67
• P/FCF Ratio: -140.01
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €1,530.97
• Price Target Upside: -4.25% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 76 Outperform
• Price Target: ¥1,526.00 ▼(-4.57% Downside)

Fuji Pharma's stock is supported by a strong financial performance and attractive valuation metrics. While technical indicators suggest moderate bullish momentum, strategic improvements in cash flow management and profitability are necessary to address potential risks.

Fuji Pharma Co., Ltd. Business Overview & Revenue Model

Company Description

Fuji Pharma Co., Ltd. (4554) is a Japanese pharmaceutical company engaged in the development, manufacturing, and marketing of prescription drugs, primarily focusing on the fields of oncology, infectious diseases, and autoimmune disorders. The company operates in both the domestic and international markets, providing a range of pharmaceutical products that cater to various medical needs. Fuji Pharma is committed to innovation and research, investing in the development of new therapies and medications to enhance patient care.

How the Company Makes Money

Fuji Pharma generates revenue through the sale of its pharmaceutical products, which include both generic and proprietary medications. The company’s revenue model is primarily based on direct sales to hospitals, pharmacies, and healthcare providers. Key revenue streams include prescription drug sales, licensing agreements, and collaborations with other pharmaceutical companies for research and development. Additionally, Fuji Pharma may benefit from partnerships with healthcare institutions for clinical trials and product testing, which can provide funding and shared resources for new drug development. The company's focus on niche therapeutic areas helps it maintain a competitive edge and potentially higher profit margins.

Fuji Pharma Co., Ltd. Financial Statement Overview

Summary

Fuji Pharma demonstrates strong revenue growth and solid balance sheet metrics, indicating financial stability. However, challenges in maintaining net profit margins and cash flow management could pose future risks. Strategic focus on improving cash flow and profitability will be crucial for continued success.

Income Statement

Fuji Pharma has demonstrated strong revenue growth with a notable increase from the previous period. The gross profit margin and EBIT margin remain solid at 40.3% and 10.9%, respectively, indicating effective cost management and operational efficiency. However, the net profit margin decreased from 13.3% to 9.1% TTM, reflecting some challenges in maintaining profitability levels.

Balance Sheet

The company maintains a healthy equity ratio of 50.6%, providing a strong buffer against liabilities. The debt-to-equity ratio is stable at 0.64, suggesting moderate leverage. Return on equity is robust at 9.2%, indicating effective utilization of shareholders' funds. However, the increase in total debt highlights potential risks if not managed carefully.

Cash Flow

While operating cash flow is currently unavailable, past performance indicates some fluctuations. The free cash flow has shown significant volatility, with periods of negative free cash flow, which may impact future investment capabilities. The lack of positive free cash flow to net income ratio underscores the need for improved cash management strategies.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	49.94B	46.14B	40.89B	35.43B	33.99B	33.79B
Gross Profit	20.08B	17.84B	16.52B	14.56B	14.75B	14.87B
EBITDA	8.19B	12.15B	7.54B	6.52B	5.46B	5.01B
Net Income	3.07B	6.15B	3.44B	2.70B	2.43B	2.08B
Balance Sheet
Total Assets	93.51B	90.00B	85.33B	75.54B	64.24B	61.96B
Cash, Cash Equivalents and Short-Term Investments	6.91B	4.58B	2.32B	3.55B	10.20B	12.04B
Total Debt	31.59B	29.25B	28.95B	24.57B	18.66B	12.19B
Total Liabilities	47.98B	44.44B	44.16B	39.73B	31.56B	22.00B
Stockholders Equity	45.52B	45.56B	41.17B	35.80B	32.68B	39.96B
Cash Flow
Free Cash Flow	0.00	-221.00M	-1.98B	-13.08B	2.10B	3.15B
Operating Cash Flow	0.00	4.15B	1.92B	-658.00M	5.99B	5.77B
Investing Cash Flow	0.00	-1.66B	-5.24B	-11.27B	-2.35B	-2.62B
Financing Cash Flow	0.00	-435.00M	1.92B	5.09B	-5.43B	450.00M

Fuji Pharma Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1599.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4554, the sentiment is Positive. The current price of 1599 is above the 20-day moving average (MA) of 1556.73, above the 50-day MA of 1506.35, and above the 200-day MA of 1383.62, indicating a bullish trend. The MACD of 27.57 indicates Negative momentum. The RSI at 58.42 is Neutral, neither overbought nor oversold. The STOCH value of 82.42 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4554.

Fuji Pharma Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4554	76 Outperform	€40.18B	13.06	7.10%	2.83%	12.06%	-51.89%
4553	70 Outperform	$139.92B	8.74	9.60%	2.74%	11.11%	-5.42%
4569	69 Neutral	¥75.80B	8.03	―	3.64%	9.83%	86.18%
4886	68 Neutral	¥56.10B	11.79	―	2.50%	6.23%	-31.45%
4551	65 Neutral	―	―	―	―	―	―
4534	64 Neutral	€104.81B	18.12	4.88%	2.64%	2.74%	36.86%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Fuji Pharma Co., Ltd. Corporate Events

Fuji Pharma Completes Stock Acquisition Rights Cancellation

Fuji Pharma Co., Ltd. has completed the acquisition and cancellation of its 1st Series of Stock Acquisition Rights, initially issued in August 2024, with a total of 23,627 units acquired and cancelled at a cost of 6,379,290 yen. This action is expected to have a negligible impact on the company’s business results for the current fiscal year.

Fuji Pharma to Acquire and Cancel Stock Acquisition Rights

Fuji Pharma Co., Ltd. has resolved to acquire and cancel all remaining stock acquisition rights from its 1st Series, originally issued to fund growth in women’s healthcare and biosimilars. This move is aimed at avoiding future dilution and will have a negligible impact on the company’s current fiscal year results, while decreasing dilutive shares by 9.8%.